Trial
NCT01884740
Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Weill Medical College of Cornell University
Collaborators
—
Condition
Glioblastoma Multiforme
Intervention
SIACI of Erbitux and Bevacizumab
Why stopped
The study was prematurely closed in December 2021 due to low accrual.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-08-09